Abstract
Background High-frequency low-tidal volume (HFLTV) ventilation is a safe and cost-effective strategy that improves catheter stability, first-pass pulmonary vein isolation, and freedom from all-atrial arrhythmias during radiofrequency catheter ablation (RFCA) of paroxysmal atrial fibrillation (PAF). However, the incremental value of adding rapid-atrial pacing (RAP) to HFLTV-ventilation has not yet been determined.
Objective To evaluate the effect of HFLTV-ventilation plus RAP during RFCA of PAF on procedural and long-term clinical outcomes compared to HFLTV-ventilation alone.
Methods Patients from the REAL-AF prospective multicenter registry, who underwent RFCA of PAF using either HFLTV+RAP or HFLTV ventilation alone from April 2020 to February 2023 were included. The primary outcome was freedom from all-atrial arrhythmias at 12-months. Secondary outcomes included procedural characteristics, long-term clinical outcomes, and complications.
Results A total of 545 patients were included (HFLTV+RAP=327 vs. HFLTV=218). There were no significant differences in baseline characteristics. No differences in procedural (HFLTV+RAP 74 [57-98] vs. HFLTV 66 [53-85.75] min, p=0.617) and RF (HFLTV+RAP 15.15 [11.22-21.22] vs. HFLTV 13.99 [11.04-17.13] min, p=0.620) times. Both groups had a similar freedom from all-atrial arrhythmias at 12 months (HFLTV+RAP 82.68% vs. HFLTV 86.52%, HR=1.43, 95% CI [0.94-2.16], p=0.093). There were no differences in freedom from AF-related symptoms (HFLTV+RAP 91.4% vs. HFLTV 93.1%, p=0.476) and rate of AF-related hospitalizations (HFLTV+RAP 1.5% vs. HFLTV 2.8%, p=0.320) between groups. Procedure-related complications were low in both groups (HFLTV+RAP 0.6% vs. HFLTV 0%, p=0.247).
Conclusion In patients undergoing RFCA for PAF, adding RAP to HFLTV-ventilation was not associated with improved procedural and long-term clinical outcomes.
Condensed Abstract High-frequency low-tidal volume (HFLTV) ventilation is a safe and cost-effective strategy that improves the efficiency and efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrial fibrillation (PAF). Our study aimed to assess the effect of HFLTV-ventilation plus rapid-atrial pacing (RAP) during RFCA of PAF on procedural and long-term clinical outcomes compared to HFLTV-ventilation alone. Patients from the REAL-AF registry who underwent PAF-RFCA from April 2020-February 2023, using HFLTV-ventilation alone or in combination with RAP, were analyzed. Our study concluded that in patients undergoing RFCA for PAF, adding RAP to HFLTV-ventilation was not associated with improved procedural and long-term clinical outcomes.
Competing Interest Statement
Dr. Osorio, Dr. Zei, Dr. Sauer, and Dr. Romero report consulting and research support from Biosense Webster. Dr. Silverstein reports consulting and honoraria from Biosense Webster. Dr. D?Souza and Dr. Rajendra report consulting from Biosense Webster. Dr. Oza reports advisory board and physician education from Biosense Webster. Dr. Thosani reports physician education from Biosense Webster. The other authors have reported no relationships relevant to the contents of this paper to disclose.
Clinical Trial
NCT04088071
Funding Statement
The REAL-AF registry is funded through an investigator-initiated research grant (Dr. Osorio, principal investigator) from Biosense Webster.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The REAL-AF registry was approved by the Western Institutional Review Board?Copernicus Group on October 31, 2018. Furthermore, institutional review boards of each participating institution approved the participation of enrolling centers adhering to the principles outlined in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All the data referred to in the manuscript is available.
Abbreviations
- HFLTV
- High-frequency low-tidal volume
- HFJV
- High-frequency jet ventilation
- HPSD
- High-power short-duration
- LVEF
- Left ventricular ejection fraction
- PAF
- Paroxysmal atrial fibrillation
- PVs
- Pulmonary vein/s
- PVI
- Pulmonary vein isolation
- RFCA
- Radiofrequency catheter ablation
- RAP
- Rapid atrial pacing
- SV
- Standard ventilation
